Charles River Magellan Collaboration Backs Zelestrocel Osteoarthritis Therapy With cGMP NGS Viral Safety Testing

The Charles River Magellan collaboration was announced on Oct. 13, 2026, when Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, said they will work together to support Magellan’s development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The release, distributed through Business Wire from Wilmington, Mass., centers on next-generation sequencing (NGS) services supporting an off-the-shelf therapy for osteoarthritis and future programs.

Under the Charles River Magellan collaboration, Charles River will contribute specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and release testing, and broader development support services. The companies state that combining Charles River’s testing and development solutions with Magellan’s advances in cell therapy development, manufacturing and clinical application is intended to drive innovation and create shared value. That aim is a stated objective, not a measured outcome.

Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing at Charles River, said that working with organizations at the forefront of innovation expands the company’s GMP testing capabilities and helps accelerate delivery of “safe, compliant therapies” to patients. She added that Charles River is excited to support Magellan as it works to advance Zelestrocel from the clinic toward potential commercialization, which is a forward-looking statement rather than a confirmed milestone.

What the Charles River Magellan Collaboration Covers for Zelestrocel Testing

Magellan Stem Cells CEO Assoc. Professor Julien Freitag said that, as the company prepares for the next stage of Zelestrocel’s development, access to advanced testing technologies and experienced partners is “critical to our success.” Magellan’s COO, Nick Bliesner, described Charles River’s GMP NGS capabilities as an innovative approach to viral safety testing that supports both product quality and regulatory readiness, and said the arrangement strengthens Magellan’s ability to advance Zelestrocel toward commercialization.

Learn More

Roche Fenebrutinib FDA Filing Accepted Under Priority Review for Relapsing and Primary Progressive Multiple Sclerosis.

The practical core of the Charles River Magellan collaboration is viral safety testing using cGMP NGS for cell and gene therapy (CGT). According to the release, this service supports a high-quality therapy development process aligned with international regulatory standards. The announcement does not specify which Zelestrocel manufacturing lots, development stages or release points will be tested, so those details are not disclosed.

The release also frames the Charles River Magellan collaboration within Charles River’s commitment to the 3Rs (Replacement, Reduction, Refinement). Charles River links its NGS service offering to its Alternative Methods Advancement Project (AMAP), which develops and implements New Approach Methodologies (NAMs) and other strategies intended to reduce reliance on animal testing while supporting efficient product development. AMAP is supported by a global, cross-functional Scientific Advisory Board led by Dr. Namandje N. Bumpus.

How the Charles River Magellan Collaboration Uses cGMP NGS for Cell and Gene Therapy

NGS is described in the release as revolutionizing how advanced therapeutics are characterized and tested, having transformed genetic analysis and pathogen detection through high throughput, scalability and speed. For a cell therapy developer approaching a pivotal program, the Charles River Magellan collaboration therefore pairs a sequencing-based approach with the viral safety demands of a donor-derived product.

Charles River states that its cGMP NGS testing services accelerate development timelines without compromising safety, and meet regulatory requirements for accuracy, reliability and compliance with GMP, FDA, EMA, and ICH Q5A and Q5B. Those are company claims made in a press release. The announcement provides no validation data or turnaround times for the Charles River Magellan collaboration.

To strengthen these capabilities, Charles River has acquired Pathoquest, which the release calls a leader in NGS solutions for in vitro characterization and quality control testing of biopharmaceutical products. The company says the acquisition lets it deliver faster and more advanced sequencing-based testing across the development pipeline. The release does not state the acquisition’s value, its closing date, or how Pathoquest’s technology will be applied to Magellan’s programs.

Learn More

ViiV Healthcare Cabenuva Meets Primary Endpoint in Phase IIIb CROWN Study of People With HIV Viremia

Zelestrocel Progress Behind the Charles River Magellan Collaboration

Magellan recently concluded Phase I/II clinical trials of Zelestrocel, its lead proprietary allogeneic, off-the-shelf stem cell therapy candidate for osteoarthritis, and is preparing to launch a pivotal Phase III program. No efficacy or safety results, enrolment numbers, trial identifiers or Phase III start dates are provided, so the Charles River Magellan collaboration reads as supporting infrastructure news rather than a clinical data update.

Magellan has vertically integrated scalable manufacturing capability into its development pathway. It has secured GMP certification from the Therapeutic Goods Administration (TGA) for its manufacturing facility in Melbourne, Australia, which the release describes as one of only four GMP certified cell therapy manufacturing facilities in Australia. Manufacturing readiness is the context the release gives for the Charles River Magellan collaboration.

Magellan describes Zelestrocel as a defined allogeneic (donor) stem cell therapy for osteoarthritis, a condition the company says affects more than 500 million people globally. The company says it aims to address unmet clinical needs with significant community benefit.

Charles River Magellan Collaboration: Cell Banking Capacity and What Remains Undisclosed

Charles River also highlights its cell banking and cell line characterization expertise in the announcement. Its cGMP-compliant cell bank production and storage services include nine ISO-6 cleanroom suites, 8-10 week cell bank completion to release, and more than 2,000 cell and viral banks produced for client programs from research and development through commercial manufacturing. The release does not say cell banking is part of the Charles River Magellan collaboration.

Several terms of the Charles River Magellan collaboration are not disclosed: financial terms, contract length, exclusivity, testing volumes and the timing of Magellan’s Phase III start. The release carries no financial guidance for Charles River tied to the agreement. Statements about commercialization, shared value and accelerated timelines should be treated as forward-looking.

This report is based solely on the Charles River news release dated Oct. 13, 2026, and the company pages it links to. The release directs investor inquiries to Todd Spencer, Corporate Vice President, Investor Relations, and media inquiries to Amy Cianciaruso, Corporate Senior Vice President, Chief Communications Officer. Further detail on the Charles River Magellan collaboration should be sought from the companies directly.

Announcement Overview

Zelestrocel and Magellan Profile

Charles River Capabilities Cited